Towards high throughput GPCR crystallography: In Meso soaking of Adenosine A2A Receptor crystals

Here we report an efficient method to generate multiple co-structures of the A2A G protein-coupled receptor (GPCR) with small-molecules from a single preparation of a thermostabilised receptor crystallised in Lipidic Cubic Phase (LCP). Receptor crystallisation is achieved following purification using a low affinity “carrier” ligand (theophylline) and crystals are then soaked in solutions containing the desired (higher affinity) compounds. Complete datasets to high resolution can then be collected from single crystals and seven structures are reported here of which three are novel. The method significantly improves structural throughput for ligand screening using stabilised GPCRs, thereby actively driving Structure-Based Drug Discovery (SBDD).

[1]  Miles Congreve,et al.  Structure-based drug design for G protein-coupled receptors. , 2014, Progress in medicinal chemistry.

[2]  S. P. Andrews,et al.  Extra-helical binding site of a glucagon receptor antagonist , 2016, Nature.

[3]  Harren Jhoti,et al.  High-throughput crystallography for lead discovery in drug design , 2002, Nature Reviews Drug Discovery.

[4]  A. Plückthun,et al.  Improving the apo-state detergent stability of NTS1 with CHESS for pharmacological and structural studies. , 2014, Biochimica et biophysica acta.

[5]  E. Segala,et al.  Structures of Human A1 and A2A Adenosine Receptors with Xanthines Reveal Determinants of Selectivity. , 2017, Structure.

[6]  Leonardo L. G. Ferreira,et al.  Molecular Docking and Structure-Based Drug Design Strategies , 2015, Molecules.

[7]  Yoko Shibata,et al.  Conformational thermostabilization of the β1-adrenergic receptor in a detergent-resistant form , 2008, Proceedings of the National Academy of Sciences.

[8]  4-hydroxy-4-methyl - piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl - benzothiazol-2-yl) - amide , 2005 .

[9]  A. Plückthun,et al.  Directed evolution of G protein-coupled receptors in yeast for higher functional production in eukaryotic expression hosts , 2016, Scientific Reports.

[10]  Randy J. Read,et al.  Phaser crystallographic software , 2007, Journal of applied crystallography.

[11]  玉一 芦田,et al.  Acta Crystallographica Section D (Biological Crystallography) の発刊に際して , 1993 .

[12]  A. IJzerman,et al.  Controlling the Dissociation of Ligands from the Adenosine A2A Receptor through Modulation of Salt Bridge Strength. , 2016, Journal of medicinal chemistry.

[13]  Ali Jazayeri,et al.  Structure of class B GPCR corticotropin-releasing factor receptor 1 , 2013, Nature.

[14]  Wei Liu,et al.  Successful Strategies to Determine High-Resolution Structures of GPCRs. , 2016, Trends in pharmacological sciences.

[15]  Brian K Shoichet,et al.  Structure-based drug screening for G-protein-coupled receptors. , 2012, Trends in pharmacological sciences.

[16]  Jonathan S. Mason,et al.  Structures of G protein-coupled receptors reveal new opportunities for drug discovery. , 2015, Drug discovery today.

[17]  Nathan Robertson,et al.  The properties of thermostabilised G protein-coupled receptors (StaRs) and their use in drug discovery , 2011, Neuropharmacology.

[18]  V. Cherezov,et al.  Crystallizing membrane proteins using lipidic mesophases , 2009, Nature Protocols.

[19]  M. Langgård,et al.  Discovery of phosphoric acid mono-{2-[(E/Z)-4-(3,3-dimethyl-butyrylamino)-3,5-difluoro-benzoylimino]-thiazol-3-ylmethyl} ester (Lu AA47070): a phosphonooxymethylene prodrug of a potent and selective hA(2A) receptor antagonist. , 2011, Journal of medicinal chemistry.

[20]  Ruben Abagyan,et al.  The GPCR Network: a large-scale collaboration to determine human GPCR structure and function , 2012, Nature Reviews Drug Discovery.

[21]  S. Iwata,et al.  Hot-Spot Residues to be Mutated Common in G Protein-Coupled Receptors of Class A: Identification of Thermostabilizing Mutations Followed by Determination of Three-Dimensional Structures for Two Example Receptors. , 2017, The journal of physical chemistry. B.

[22]  R. Stevens,et al.  Microscale fluorescent thermal stability assay for membrane proteins. , 2008, Structure.

[23]  R. Stevens,et al.  Structural Basis for Allosteric Regulation of GPCRs by Sodium Ions , 2012, Science.

[24]  P. Evans,et al.  Scaling and assessment of data quality. , 2006, Acta crystallographica. Section D, Biological crystallography.

[25]  P. Emsley,et al.  Features and development of Coot , 2010, Acta crystallographica. Section D, Biological crystallography.

[26]  P. Singh,et al.  The in vitro pharmacology of ZM 241385, a potent, non‐xanthine, A2a selective adenosine receptor antagonist , 1995, British journal of pharmacology.

[27]  A. Doré,et al.  Structure of class C GPCR metabotropic glutamate receptor 5 transmembrane domain , 2014, Nature.

[28]  P. Zwart,et al.  Towards automated crystallographic structure refinement with phenix.refine , 2012, Acta crystallographica. Section D, Biological crystallography.

[29]  A. Knight,et al.  Antagonists of the human A(2A) adenosine receptor. 4. Design, synthesis, and preclinical evaluation of 7-aryltriazolo[4,5-d]pyrimidines. , 2009, Journal of medicinal chemistry.

[30]  M. Congreve,et al.  Structure of the adenosine A(2A) receptor in complex with ZM241385 and the xanthines XAC and caffeine. , 2011, Structure.

[31]  R. V. van Montfort,et al.  Structure-based design of molecular cancer therapeutics. , 2009, Trends in biotechnology.

[32]  Christopher G. Tate,et al.  Biophysical Fragment Screening of the β1-Adrenergic Receptor: Identification of High Affinity Arylpiperazine Leads Using Structure-Based Drug Design , 2013, Journal of medicinal chemistry.

[33]  Vincent B. Chen,et al.  Correspondence e-mail: , 2000 .

[34]  E. Segala,et al.  Biosensor‐based affinities and binding kinetics of small molecule antagonists to the adenosine A2A receptor reconstituted in HDL like particles , 2015, FEBS letters.

[35]  Randy J. Read,et al.  Overview of the CCP4 suite and current developments , 2011, Acta crystallographica. Section D, Biological crystallography.

[36]  Jonathan S. Mason,et al.  Discovery of 1,2,4-Triazine Derivatives as Adenosine A2A Antagonists using Structure Based Drug Design , 2012, Journal of medicinal chemistry.